Medicine faculty showcase their research at ASH

Friday, December 15, 2017

Department of Medicine faculty are attending the American Society of Hematology's (ASH) 59th Annual Meeting & Exposition in Atlanta this week.

Some highlights include:

A study on "Updated Prognostic Tools Needed in the Era of Novel Therapies for Chronic Lymphocytic Leukemia" by Danielle Brander, MD, assistant professor of medicine (Hematologic Malignancies and Cellular Therapy).

A Q&A with Thomas LeBlanc, MD, MA, MHS, associate professor of medicine (Hematologic Malignancies and Cellular Therapy), on The Value of ePROs in Oncology and research on "Misperceptions About Prognosis in Acute Myeloid Leukemia Highlight the Need for Better Patient-Physician Communication" and "Transfusion Dependence May Hinder Quality End-of-Life Care in Medicare Beneficiaries With Leukemia."

"Novel Mechanism for Chronic Graft-Versus-Host Disease Suggests New Treatment Paths" presented by Amy N. Suthers, PhD, on behalf of the Duke research team headed by Stefanie Sarantopoulos, MD, PhD, associate professor of medicine (Hematologic Malignancies and Cellular Therapy).

A study by Sandeep Dave, MD, MS, professor of medicine (Hematologic Malignancies and Cellular Therapy), that highlights genetic diversity and a potential new treatment target in diffuse large B-Cell Lymphoma.

Plus research by Andrea Sitlinger, MD; Matthew McKinney, MD; Anthony Sung, MD; Hisayuki Yao, MD, PhD; and Cristina Gasparetto, MD.

Learn more and read a full round up by Duke Cancer Institute.